Examining the use of the transdermal scopolamine patch in the prevention of postdischarge nausea and/or vomiting: A secondary analysis
James I. Masiongale, CRNA; Jane Garvin, RN; Marguerite J. Murphy, RN; Stephen W. Looney
- Sigma Affiliation
- Beta Omicron
- Contributor Affiliation(s)
- Georgia Regents University, Augusta, Georgia, USA
Visits vs Downloads
Visitors - World Map
Top Visiting Countries
Top Visiting Cities
Visits (last 6 months)
Downloads (last 6 months)
Popular Works for Masiongale, James I. by View
Popular Works for Masiongale, James I. by Download
Session presented on Sunday, November 8, 2015: Postdischarge nausea and/or vomiting (PDNV) is estimated to affect up to 50% of patients undergoing general anesthesia. New guidelines recommend long acting antiemetics for those considered to be at risk for PDNV. Therefore, the purpose of this study was to examine the use of the long acting antiemetic, transdermal scopolamine patch (TDS), and the subsequent incidence of nausea and vomiting among ambulatory surgical patients. From the multicenter observational cohort study of 2170 adult ambulatory surgical patients collected from 2007-2008, data were analyzed from 2098 participants with sufficient information to calculate risk scores. The parent study contained variables of interest that were recoded for this study. Descriptive statistics were used to characterize participants in terms of demographics, risk for nausea and/or vomiting, surgical procedure, TDS use (none, during anesthesia, or following the operation in the postanesthesia care unit), and incidence of nausea and/or vomiting. On average, participants were overweight (body mass index = 28.3, SD = 6.9), approximately 50 years of age (M = 49.7, SD = 15.4) and primarily female (65%). Common surgical procedures were general surgery (N = 426, 20%), gynecologic (N = 230, 11%), knee arthroscopy (N = 222, 11%), and breast (N = 219, 10%). TDS was used in less than 4% of the participants; no TDS (N = 2020, 96%), TDS during anesthesia (N = 71, 3.4%), and TDS in PACU (N = 7, <1%). For those qualified to receive a long acting antiemetic based on risk scores, less than 1% received TDS. Over 90% (N = 64) of those receiving TDS during anesthesia had a PDNV Risk Score of +/- 3; 86% (N = 6) of those receiving TDS in PACU had a PDNV Risk Score of +/- 3. Given the expected PDNV incidence of 20,30,50,60, and 80% for a risk score of 1,2,3,4,5, respectively, those not receiving TDS experienced PDNV at the expected incidence based on PDNV risk score (18,31,49,61,and 82% respectively). Those receiving TDS during anesthesia generally had an incidence of PDNV less than expected (0, 40, 37, 53,and 71% respectively). Six of the seven receiving TDS in PACU had a postoperative nausea and/or vomiting risk score +/- 3. Five of the seven receiving TDS in PACU had nausea and/or vomiting while in the PACU. Those with a PDNV risk score of 3, 4, or 5 receiving TDS in PACU had higher incidence of PDNV than expected (67, 100, and 100%); this was likely due to providers reserving TDS for those with the highest risk scores and those already experiencing nausea or vomiting in the PACU. Findings from this study highlight the limited use of TDS as a long acting antiemetic in ambulatory surgical settings and the potential value when given during anesthesia. While this cohort study has limitations, further study is needed to examine the effect of TDS on the individual components of PDNV (nausea, vomiting, nausea or vomiting, and nausea and vomiting), as well as severity of PDNV, using a randomized controlled trial to examine TDS across all levels of PDNV risk score.
43rd Biennial Convention 2015 Theme: Serve Locally, Transform Regionally, Lead Globally.
Items submitted to a conference/event were evaluated/peer-reviewed at the time of abstract submission to the event. No other peer-review was provided prior to submission to the Henderson Repository, unless otherwise noted.
|Review Type||Abstract Review Only: Reviewed by Event Host|
|Keywords||Transdermal Scopolamine Patch;
Postdischarge Nausea and/or Vomiting;
Postdischarge Nausea and/or Vomiting Risk Factors
All rights reserved by the author(s) and/or publisher(s) listed in this item record unless relinquished in whole or part by a rights notation or a Creative Commons License present in this item record.
All permission requests should be directed accordingly and not to the Sigma Repository.
All submitting authors or publishers have affirmed that when using material in their work where they do not own copyright, they have obtained permission of the copyright holder prior to submission and the rights holder has been acknowledged as necessary.
Showing items related by title, author, creator and subjects.
Re-examining metoclopramides' role in the prevention of postoperative nausea and/or vomiting: A secondary analysis Masiongale, Amy; Garvin, Jane; Murphy, Marguerite J.; Looney, Stephen W. (2016-03-21)Session presented on Monday, November 9, 2015 and Tuesday, November 10, 2015: Postoperative nausea and/or vomiting (PONV) continue to be two of the most undesirable and distressing complications following general anesthesia, ...
Evaluation of the implementation of ASPAN's evidence-based clinical practice guideline for the prevention and/or treatment of postoperative nausea and vomiting Stephens, Lisa (2016-03-17)Session presented on Friday, July 24, 2015: Evaluation of the Implementation of the ASPAN's Evidence-Based Clinical Practice Guideline for the Prevention and/or Treatment of Postoperative Nausea and Vomiting Lisa Stephens ...
Factors associated with high dose Benzodiazepines use in long-term users with depressive and/or anxiety disorders Chen, Yu-TingWe expect the findings draw attendees' attention on the high dose of benzodiazepines (BZDs) use among this population and its risk factors, and providing information for healthcare providers to develop additional strategies ...
Factors that challenge and/or facilitate a military student’s transition to the civilian nursing classroom Cox, Catherine WilsonMilitary nursing students bring a variety of experiences to the classroom but they may also present with some unique challenges that educators should be cognizant of in order to successfully transition them to the civilian ...
Fasting used to enhance cancer treatment for patients who are immunocompromised and/or undergoing treatment Burnett, Lorena C.This review aims to answer the question of whether fasting will help protect the immune system against the toxicity of cancer treatment and increase efficacy of treatment as well as decreasing some of the side effects.